Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance

Cancer Research

Volumn 71, Issue 8, 2011, Pages 3029-3041

  Shi, Zhi ^a,b   Tiwari, Amit K ^a   Shukla, Suneet ^c   Robey, Robert W ^d   Singh, Satyakam ^a   Kim, In Wha ^c   Bates, Susan E ^d   Peng, Xingxiang ^a   Abraham, Ioana ^a   Ambudkar, Suresh V ^c   Talele, Tanaji T ^a   Fu, Li Wu ^b   Chen, Zhe Sheng ^a  

^a ST JOHN'S UNIVERSITY   (United States)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^c Laboratory of Cell Biology   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ADENOSINE TRIPHOSPHATASE; BREAST CANCER RESISTANCE PROTEIN; CISPLATIN; COLCHICINE; EMTRICITABINE; ESTRADIOL 17 GLUCURONIDE; FLAVOPIRIDOL; IODINE 125; METHOTREXATE; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; PRAZOSIN; SILDENAFIL; VINBLASTINE;

ARTICLE; CELL LEVEL; CONTROLLED STUDY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RESISTANCE; DRUG SENSITIVITY; DRUG TRANSPORT; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PHOTOAFFINITY LABELING; PRIORITY JOURNAL; PROTEIN FUNCTION;

ADENOSINE TRIPHOSPHATASES; ATP-BINDING CASSETTE TRANSPORTERS; BORON COMPOUNDS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; KB CELLS; METHOTREXATE; MITOXANTRONE; MODELS, MOLECULAR; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; PACLITAXEL; PIPERAZINES; PRAZOSIN; PURINES; SULFONES;

EID: 79954569834     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-3820     Document Type: Article

References (38)

1. Dean M, Rzhetsky A, Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 2001;11:1156-66. (Pubitemid 32677289)
2. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006;5:219-34. (Pubitemid 43336035)
3. Germann UA, Ford PJ, Shlyakhter D, Mason VS, Harding MW. Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ ADR cells expressing the multidrug resistance-associated protein MRP. Anticancer Drugs 1997;8:141-55. (Pubitemid 27102229)
4. Qadir M, O'Loughlin KL, Fricke SM, Williamson NA, Greco WR, Minderman H, et al. Cyclosporin A is a broad-spectrum multidrug resistance modulator. Clin Cancer Res 2005;11:2320-6. (Pubitemid 40490193)
5. Minderman H,O'Loughlin KL, Pendyala L, Baer MR. VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Clin Cancer Res 2004;10:1826-34. (Pubitemid 38435574)
6. Dantzig AH, Shepard RL, Pratt SE, Tabas LB, Lander PA, Ma L, et al. Evaluation of the binding of the tricyclic isoxazole photoaffinity label LY475776 to multidrug resistance associated protein 1 (MRP1) orthologs and several ATP- binding cassette (ABC) drug transporters. Biochem Pharmacol 2004;67:1111-21. (Pubitemid 38296790)
7. Evers R, Kool M, Smith AJ, van Deemter L, de Haas M, Borst P. Inhibitory effect of the reversal agents V-104, GF120918 and Pluronic L61 on MDR1 Pgp-, MRP1- and MRP2-mediated transport. Br J Cancer 2000;83:366-74. (Pubitemid 30453578)
8. Sissung TM, Gardner ER, Piekarz RL, Howden R, Chen X, Woo S, et al. Impact of ABCB1 allelic variants on QTc interval prolongation. Clin Cancer Res 2011;17:937-46.
9. Shi Z, Tiwari AK, Shukla S, Robey RW, Kim IW, Parmar S, et al. Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol 2009;77:781-93.
10. Dai CL, Tiwari AK, Wu CP, Su XD, Wang SR, Liu DG, et al. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res 2008;68:7905-14.
11. Shi Z, Peng XX, Kim IW, Shukla S, Si QS, Robey RW, et al. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2- mediated drug resistance. Cancer Res 2007;67:11012-20. (Pubitemid 350145931)
12. Tiwari AK, Sodani K, Wang SR, Kuang YH, Ashby CR Jr, Chen X, et al. Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem Pharmacol 2009;78:153-61.
13. Francis SH, Sekhar KR, Rouse AB, Grimes KA, Corbin JD. Single step isolation of sildenafil from commercially available Viagra tablets. Int J Impot Res 2003;15:369-72. (Pubitemid 37376943)
14. Akiyama S, Fojo A, Hanover JA, Pastan I, Gottesman MM. Isolation and genetic characterization of human KB cell lines resistant to multiple drugs. Somat Cell Mol Genet 1985;11:117-26. (Pubitemid 15149285)
15. Taguchi Y, Yoshida A, Takada Y, Komano T, Ueda K. Anti-cancer drugs and glutathione stimulate vanadate-induced trapping of nucleotide in multidrug resistance-associated protein (MRP). FEBS Lett 1997;401:11-4. (Pubitemid 27051248)
16. Robey RW, Honjo Y, Morisaki K, Nadjem TA, Runge S, Risbood M, et al. Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity. Br J Cancer 2003;89:1971-8. (Pubitemid 37533279)
17. Robey RW, Medina-Perez WY, Nishiyama K, Lahusen T, Miyake K, Litman T, et al. Overexpression of the ATP-binding cassette halftransporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells. Clin Cancer Res 2001;7:145-52. (Pubitemid 32110217)
18. Chen ZS, Robey RW, Belinsky MG, Shchaveleva I, Ren XQ, Sugimoto Y, et al. Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: Effects of acquired mutations at R482 on methotrexate transport. Cancer Res 2003;63:4048-54. (Pubitemid 36917926)
19. Ambudkar SV. Drug-stimulatable ATPase activity in crude membranes of human MDR1-transfected mammalian cells. Methods Enzymol 1998;292:504-14. (Pubitemid 29343911)
20. Shukla S, Robey RW, Bates SE, Ambudkar SV. The calcium channel blockers, 1,4-dihydropyridines, are substrates of the multidrug resistance- linked ABC drug transporter, ABCG2. Biochemistry 2006; 45:8940-51. (Pubitemid 44100690)
21. Sauna ZE, Ambudkar SV. Evidence for a requirement for ATP hydrolysis at two distinct steps during a single turnover of the catalytic cycle of human P-glycoprotein. Proc Natl Acad Sci U S A 2000;97:2515-20. (Pubitemid 30159202)
22. Jorgensen WL, Maxwell DS, Tirado-Rives JJ. Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. J Am Chem Soc 1996;118:11225-36. (Pubitemid 26399746)
23. Aller SG, Yu J, Ward A, Weng Y, Chittaboina S, Zhuo R, et al. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 2009;323:1718-22.
24. Cornwell MM, Gottesman MM, Pastan IH. Increased vinblastine binding to membrane vesicles from multidrug-resistant KB cells. J Biol Chem 1986;261:7921-8. (Pubitemid 17208724)
25. Honjo Y, Hrycyna CA, Yan QW, Medina-Perez WY, Robey RW, van de Laar A, et al. Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res 2001;61:6635-9. (Pubitemid 32896477)
26. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999;39:361-98. (Pubitemid 29222564)
27. Raub TJ. P-glycoprotein recognition of substrates and circumvention through rational drug design. Mol Pharm 2006;3:3-25. (Pubitemid 43331747)
28. Pleban K, Ecker GF. Inhibitors of p-glycoprotein-lead identification and optimisation. Mini Rev Med Chem 2005;5:153-63.
29. Ekins S. Drug transporter pharmacophores. Transporters Drug Carriers 2009;44:215-21.
30. Loo TW, Clarke DM. Mutational analysis of ABC proteins. Arch Biochem Biophys 2008;476:51-64.
31. Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead GJ, Naylor AM, et al. Sildenafil: An orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996;8:47-52.
32. Milligan PA, Marshall SF, Karlsson MO. A population pharmacokinetic analysis of sildenafil citrate in patients with erectile dysfunction. Br J Clin Pharmacol 2002;53Suppl 1:S45-52.
33. Sarfati M, Mateo V, Baudet S, Rubio M, Fernandez C, Davi F, et al. Sildenafil and vardenafil, types 5 and 6 phosphodiesterase inhibitors, induce caspase-dependent apoptosis of B-chronic lymphocytic leukemia cells. Blood 2003;101:265-9. (Pubitemid 36025917)
34. Serafini P, Meckel K, Kelso M, Noonan K, Califano J, Koch W, et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med 2006;203:2691-702. (Pubitemid 44833345)
35. Black KL, Yin D, Ong JM, Hu J, Konda BM, Wang X, et al. PDE5 inhibitors enhance tumor permeability and efficacy of chemotherapy in a rat brain tumor model. Brain Res 2008;1230:290-302.
36. Di X, Gennings C, Bear HD, Graham LJ, Sheth CM, White KL Jr, et al. Influence of the phosphodiesterase-5 inhibitor, sildenafil, on sensitivity to chemotherapy in breast tumor cells. Breast Cancer Res Treat 2010;124:349-60.
37. Das A, Durrant D, Mitchell C, Mayton E, Hoke NN, Salloum FN, et al. Sildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfunction. Proc Natl Acad Sci U S A 2010;107:18202-7.
38. Dundar M, Kocak I, Dundar SO, Erol H. Evaluation of side effects of sildenafil in group of young healthy volunteers. Int Urol Nephrol 2001;32:705-8. (Pubitemid 34272340)